Zacks.com on MSN

MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...
Business Wire

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Isl…

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Medscape

Important Long-COVID Lessons From AIDS Researchers

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...
Clinical Trials Arena on MSN

MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial

MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
The Healthy @Reader's Digest on MSN

12 Silent Signs of Skin Cancer You’re Probably Ignoring

Subtle signs of skin cancer you shouldn't ignore When the weather gets warmer and daylight hours longer, people are more likely to spend time outdoors in the sun. This also means there’s an increased ...

The Biotech Growth Trust PLC - Half-year Financial Report

The Biotech Growth Trust PLC - Half-year Financial Report ...
Valley Voice

Tuberculosis cases on the rise in Tulare County, officials encourage screening

Tulare County is experiencing an increase in cases of Tuberculosis, also known as TB, which is a serious illness caused by the bacteria Mycobacterium tuberculosis. Public Health officials encourage ...